Last reviewed · How we verify
Capecitabine and Sorafenib — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Capecitabine and Sorafenib (Capecitabine and Sorafenib) — SCRI Development Innovations, LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Capecitabine and Sorafenib TARGET | Capecitabine and Sorafenib | SCRI Development Innovations, LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Capecitabine and Sorafenib CI watch — RSS
- Capecitabine and Sorafenib CI watch — Atom
- Capecitabine and Sorafenib CI watch — JSON
- Capecitabine and Sorafenib alone — RSS
Cite this brief
Drug Landscape (2026). Capecitabine and Sorafenib — Competitive Intelligence Brief. https://druglandscape.com/ci/capecitabine-and-sorafenib. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab